SuperworthOutlook Therapeutics revenue OTLK
Sales by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q3 FY26
- $8.7K
- −99% on a year earlier
- Fiscal year 2019
- $8.1M
- +164% on the year before
Outlook Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY26, it was $8.7K, down 99% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2019 | $8.1M | +164% |
| FY2018 | $3.1M | −19% |
| FY2017 | $3.8M | +28% |
| FY2016 | $3M | −43% |
| FY2015 | $5.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $8.7K | −99% | n/a | |
| Q2 FY26 | $127.4K | n/a | n/a | |
| Q1 FY26 | −$1.2M | n/a | n/a | |
| Q3 FY25 | $1.5M | n/a | n/a | |
| Q4 FY19 | $5.9M | +658% | $8.1M | |
| Q3 FY19 | $583.8K | −24% | $3.1M | |
| Q2 FY19 | $641.1K | −17% | $3.3M | |
| Q1 FY19 | $1.1M | +38% | $3.4M | |
| Q4 FY18 | $771.9K | −73% | $3.1M | |
| Q3 FY18 | $771.9K | +155% | $5.2M | |
| Q2 FY18 | $771.9K | +155% | $4.7M | |
| Q1 FY18 | $771.9K | +155% | $4.3M |
Against its peers
Companies in Healthcare nearest Outlook Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| OTLKOutlook Therapeutics | n/m | |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| ICCCImmucell | $30.7M | +8% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ELMDElectromed | $73.8M | +15% a year |
| UTMDUtah Medical Products | $36.1M | −7% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| INFUInfuSystem | $143.3M | +2% a year |
| Peer median | $79.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Outlook Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.